Abstract 383P
Background
The body mass index (BMI) before therapy shows a variety of progression free survival (PFS), it was said in the BMI study <18.5 kg/m2, had a worse progression free survival, compared to BMI 18.5-24.9 kg/m and BMI >24.9 kg/m2. The neutrophil lymphocyte ratio before therapy showed a variety of progression free survival (PFS). It was said that NLR ≥ 3 patients study have a better progression free survival compared to those < 3, but these results are still contradictory. The aim of this study was to determine body mass index and neutrophil to lymphocyte ratio before therapy to predict 3-year progression free survival in patients with locally advanced nasopharyngeal carcinom.
Methods
Patients with locally advanced nasopharyngeal carcinoma (N=289) from 2015 until 2017 who underwent chemoradiation with and without adjuvant or neoadjuvant chemotherapy were enrolled. Body mass index before therapy was classified as <18.5 (underweight), 18.5-24.9 (normal), and >24.9 (overweight or obese) and the neutrophil to lymphocyte ratio before therapy was categorized as ≥3 and <3, using the Cox proportional hazard and Kaplan-Meier models.
Results
Body mass index 18.5-24.9 and 24.9 on Cox regression has a better 3-year PFS with adjusted hazard ratio (HR = 0.219; CI = 1.43-1.59; p = 0.025 and HR = 0.136 ; CI = 1.51-1.76; p = 0.025 ), BMI <18.5 indicates a lower 3-year PFS (HR=1.644; CI=1.28-1.56; P=0.001). While NLR ≥3 before therapy had a better 3-year PFS (HR=0.152; CI 1.37-1.53, p=0.001) than NLR <3 (HR=1.603; CI 1.52-1.69, p=0.013.
Conclusions
Patients with BMI<18.5 before therapy had a lower 3-year PFS, and BMI>24.9 had a 3-year higher PFS than the normal weight group and NLR ≥3 had a higher PFS than under 3. This study provides a good understanding better between BMI and PFS and NLR and PFS, but further research is needed to confirm the result in different populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract